Future Market Insights.png
Alzheimer's Therapeutics Market Aims to Surpass US$ 7,359.7 Million by 2033 with Tailored Treatments | Future Market Insights, Inc. NEWARK, Del, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The estimated value of the worldwide Alzheimer's in 2023 is US$ 3,052.3 million. By 2033, the market for Alzheimer's treatments is predicted to grow at...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
28 juin 2021 07h00 HE | Amydis, Inc.
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
5ef2af588104f70ce6d76d97_1.jpg
Alzheimer's Diagnostics a Medical Breakthrough Attained by Global WholeHealth Partners Corp. (OTC: GWHP) as a Leading Researcher, Believes an Alzheimer's Test Will Save Lives
19 avr. 2021 06h30 HE | Global WholeHealth Partners Corp.
SAN CLEMENTE, CA, April 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
11 janv. 2021 07h00 HE | Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Diagnostics Named to San Diego Venture Group’s (SDVG) 2017 Cool Companies List
30 mai 2017 09h00 HE | Amydis Diagnostics, Inc.
SAN DIEGO, May 30, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Diagnostics Adds Veteran Drug Development Executive and Chief Medical Officer to Management Team
17 mai 2017 09h00 HE | Amydis Diagnostics, Inc.
SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease
20 mars 2017 07h07 HE | Amydis Diagnostics, Inc.
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer's Disease
29 sept. 2015 09h00 HE | Amydis, Inc.
SAN DIEGO, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...